Retinoblastoma Gene Product and P21 (WAF1, CIP1) Protein Expression in Non Hodgkin's Lymphomas: A Multivariate Survival Analysis

References

• Goodrich D. W., Wang N. P., Qian Y.-W., Lee E. Y.-Y.P., Lee W. H. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991; 67: 293–302
   PubMed Web of Science ®Google Scholar
• Coppola J. A., Lewis B. A., Cole M. D. Increased retinoblastoma gene expression is associated with late stages of differentiation in many different cell types. Oncogene 1990; 5: 1731–1733
   PubMed Web of Science ®Google Scholar
• Stein G. H., Beeson M., Gordon I. Failure to phosphorylate the retinoblastoma gene product in senescent human fibrolasts. Science 1990; 249: 666–669
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S., Dohner H., Bulgay-Morschel M., Weitz S., Bentz M., Lister P. High frequency of monoallelic retinoblastoma gene deletion in B-cell chronic lymphocytic leukemia revealed by interphase cytogenetics. Blood 1993; 81: 2118–2124
   PubMed Web of Science ®Google Scholar
• Kornblau S. M., Chen N., del Giglio A., O'Brien S., Deisseroth A. B. Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia. Cancer Research 1994; 54: 242–246
   PubMed Web of Science ®Google Scholar
• Haber M. M., Inghirami G., Dalla-Favera R., Knowles D. M. Retinoblastoma (RB) gene product expression in B-cell non-Hodgkin's lymphomas (NHLs) and lymphoid leukemias (LLs). Laboratory Investigation 1991; 64: 73A
   Web of Science ®Google Scholar
• Weide R., Tiemann M., Pfluger K. H., Koppler H., Parvizi B., Nacker H. H., Kreipe H. H., Havemann K., Parwaresch M. R. Altered expression of the retinoblastoma gene product in human high-grade non-Hodgkin's lymphomas. Leukemia 1994; 8: 97–101
   PubMed Web of Science ®Google Scholar
• Perez de Castro I. P., Malumbres M., Santos J., Pellicer A., Fernandez-Piquerai J. Cooperative alterations of Rb pathway regulators in mouse primary T cell lymphomas. Carcinogenesis 1999; 20: 1675–1682
   PubMed Web of Science ®Google Scholar
• Wada M., Okamura M., Teramura M., Masuda M., Motoji T., Mizoguchi H. Frequent chromosome arm 13q deletion in aggressive non-Hodgkin's lymphoma. Leukemia 1999; 13: 792–798
   PubMed Web of Science ®Google Scholar
• El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potent mediator of p53 tumor suppression. Cell 1993; 75: 817–825
   PubMed Web of Science ®Google Scholar
• Luo Y., Hurwitz J., Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21 CIP 1. Nature 1995; 375: 159–161
   PubMed Web of Science ®Google Scholar
• Zhang H., Hannon G. J., Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Developments 1994; 8: 1750–1798
   PubMed Web of Science ®Google Scholar
• Zhang W., Grasso L., McClain C. D., Gambel A. M., Cha Y., Travali S., Deisseroth A. B., Mercer W. E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Research 1995; 55: 668–674
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Musshoft K., Smithers D. W., Tubiana M. Report of the committee on Hodkgin's disease staging classification. Cancer Research 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Binet J. L., Le Porrier M., Dighiero G., Charron D., D'Athis P., Vaugier G., Merle Beral H., Natali J. C., Raphael M., Nizet B., Folleson J. Y. A clinical staging system for chronic lymphocytic leukemia. Cancer 1977; 40: 855–864
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Longo D. L., Coiffier B., Fisher R. L., Cabanillas F., Cavalli F., Nadler L. M., de Vita V. T., Lister T. A., Armitage J. O. Lymphoma classification: the gap between biology and clinical management is closing. Blood 1996; 88: 4085–4089
   PubMed Web of Science ®Google Scholar
• Harris N., Jaffe E. S., Stein H., Banks P., Chan K. C., Cleary M. C., Delsol G., DeWolf-Peeters C., Falini B., Gatter K. C., Grogan T. M., Isaacson P. G., Knowles D. M., Mason D. Y., Muller-Hermelink H. K., Pileri S. A., Piris M. A., Ralfkiaer E. D., Warnke R. A. A revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Cattoretti G., Becker M. H.G., Key G., Duchrow M., Schluter C., Galle J., Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. Journal of Pathology 1992; 168: 357–363
   PubMed Web of Science ®Google Scholar
• Norton A. J., Jordan S., Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. Journal of Pathology 1994; 173: 371–379
   PubMed Web of Science ®Google Scholar
• Munck-Wikland E., Edstrom S., Jungmark E., Kuylenstierna R., Lindholm J., Auer G. Nuclear DNA content, proliferating cell nuclear antigen (PCNA) and p53 immunostaining in predicting progression of laryngeal cancer in situ lesions. International Journal of Cancer 1994; 56: 95–99
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C., Waringer D., Petrylak D., Dalbagni G., Fair W. R., Fuks Z., Reuter V. E. Altered expression of the retinoblastoma gene product is a prognostic indicator in bladder cancer. Journal of National Cancer Institute 1992; 84: 1251–1256
   PubMed Web of Science ®Google Scholar
• Ginsberg A. M., Raffeld M., Cossman J. Inactivation of the retinoblastoma gene in human lymphoid neoplasms. Blood 1991; 77: 833–840
   PubMed Web of Science ®Google Scholar
• Grierson A. J., Hodgkins M. A., Hancock B. W., Goepel J. R., Royds J., Goyns M. H. Investigation of the RB-1 tumour suppressor gene in a United Kingdom series of non-Hodgkin's lymphomas. Leukemia and Lymphoma 1996; 23: 353–363
   PubMed Web of Science ®Google Scholar
• Geradts J., Andriko J. W., Abbondanzo S. L. Loss of tumor suppressor gene expression in high grade but not low-grade non-Hodgkin's lymphomas. American Journal of Clinical Pathology 1998; 109: 669–674
   PubMed Web of Science ®Google Scholar
• Nguyen P. L., Zukerberg L. R., Benedict W. F., Harris N. L. Immunohistochemical detection of p53, bcl-2 and retinoblastoma proteins in follicular lymphoma. American Journal of Clinical Pathology 1996; 105: 538–543
   PubMed Web of Science ®Google Scholar
• Sinclair A. J., Frost V. Loss of functional pRB is not a ubiquitous feature of B-cell malignancies. British Journal of Cancer 1999; 80: 670–675
   PubMed Web of Science ®Google Scholar
• Reissmann P. T., Koga H., Takahashi R., Figlin R. A., Holenes E. C., Piantadosi S., Cardon-Cardo C., Slomon D. J. Inactivation of the retinoblastoma susceptibility gene in non-small cell lung cancer. Oncogene 1993; 8: 1913–1919
   PubMed Web of Science ®Google Scholar
• Xu H. J. Altered retinoblastoma (Rb) protein expression in human malignancies. Advances in Anatomic Pathology 1995; 2: 213–226
   Google Scholar
• Martinez J., Piris M., Sanchez-Beato M., Villuendas R., Orraadre J., Algara P., Sanchez-Verde L., Martinez P. Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki-67 growth fraction. Journal of Pathology 1993; 169: 405–412
   PubMed Web of Science ®Google Scholar
• Jares P., Campo E., Pinyol M., Bosch F., Miquel R., Fernandez P., Sanchez-Beato M., Soler F., Perez-Losada A., Nayach I., Mallofre C., Piris M., Monserrat E., Cardesa A. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD 1/CCND 1) mRNA levels and proliferative activity. American Journal of Pathology 1996; 148: 1591–1600
   PubMed Web of Science ®Google Scholar
• Stefanaki K., Tzardi M., Kouvidou C., Chaniotis V., Bolioti M., Vlychou M., Zois M., Kakolyris S., Delides G., Rontogianni D., Georgoulias V., Kanavaros P. Expression of p53, p21, mdm 2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue. Anticancer Research 1998; 18: 2403–2408
   PubMed Web of Science ®Google Scholar
• Xu H. J., Hu S. X., Benedict W. F. Lack of nuclear RB protein staining in Go/middle G1 cells: correlation to changes in total Rb protein level. Oncogene 1991; 6: 1139–1144
   PubMed Web of Science ®Google Scholar
• Zhang W., Kornblau S. M., Kobayashi T., Gambel A., Claxton D., Deisseroth A. B. High levels of constitutive WAF1/Cip1 protein are associated with chemo-resistance in clinical acute myelogenous leukemia. Clinical Cancer Research 1995; 1: 1051–1057
   PubMed Web of Science ®Google Scholar
• Shiohara M., El-Deiry W. S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D.-L., Vogelstein B., Koeffler P. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781–3784
   PubMed Web of Science ®Google Scholar
• El-Deiry W. S., Tokino X., Waldman T., Oliner J., Velculescu E., Burrel M., Hill D., Healy E., Rees J., Hamilton S., Kinzler K., Vogelstein B. Topological control of p21 WAF1/cip1 expression in normal and neoplastic tissues. Cancer Research 1995; 55: 2910–2919
   PubMed Web of Science ®Google Scholar
• Jung J. M., Bruner J. M., Ruan S., Langford L., Kyritsis A., Kobayashi T., Levin V., Zhang W. Increased levels of p21 WAF1/CIP1 in human brain tumors. Oncogene 1995; 11: 2021–2028
   PubMed Web of Science ®Google Scholar
• Chilosi M., Doglioni C., Magalini A., Inghirami G., Krampera M., Nadali G., Rahal D., Pedron S., Benedetti A., Scardoni M., Macri E., Lestani M., Menestrina F., Pizzolo G., Scarpa A. p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood, 88: 4012–4020
   PubMed Web of Science ®Google Scholar
• DiGiuseppe J. A., Redstone M. S., Yeo C. J., Kern S. F., Hrulan R. H. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. American Journal of Pathology 1995; 147: 884–888
   PubMed Web of Science ®Google Scholar
• Sanchez E., Chacon I., Plaza M. M., Munoz E., Cruz M. A., Martinez B., Lopez L., Martinez-Montero J. C., Orradre J. L., Saez A. I., Garcia J. F., Dins M. A. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. Journal of Clinical Oncology 1998; 16: 1931–1939
   PubMed Web of Science ®Google Scholar